Skip to contentG
Guided Therapeutics Inc
G
GTHPGuided Therapeutics Inc Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.00K$1.00Kderived−96.9% vs Q4 2023 Net Income-$652.00K-$652.00KderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Guided Therapeutics Inc · CIK 924515 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$2,000N/M Operating Incomederived-$533,000N/M Operating Cash Flowderived-$332,000N/M Free Cash Flowderived-$332,000N/M Margins · derivedGross margin-200.0%−250.0 pt vs Q4 2023
Operating margin-53300.0%−51781.3 pt vs Q4 2023
Net margin-65200.0%−63993.8 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 31, 2025 · 90 d after period end